The intractable with taxanes (paclitaxel, docetaxel, Abraxane), just, are abundant. in the greatest Side effects such as inessential neuropathy and neutropenia irritate booming group therapy. in the greatest Additionally, taxanes are substrates in the direction of ABCB1 (aka P-glycoprotein [P-gp] or MDR1). in the greatest Chronic or overexposure to taxanes causes upregulation of ABCB1, which in veer induces MDR and decreases intracellular build-up of the hallucinogenic. in the greatest Finally, taxanes be hardship with frail solubility, making it needful to control in tainted doses and run frequencies, both of which also increases the drug’s propensity in the direction of guerrilla.
This is in veer, decreases the drug’s effectiveness at eradicating tumor cells and increases guerrilla.
The zip to advance an oral taxane with tainted bioavailability, frail side effects and frail or null pgp activation is not suppletive, although filled with setbacks. in the greatest Bristol-Meyers Squibb has tried with BMS-275183 and Taxolog with Milataxel.
Before we inaugurate, let’s in the first fix national that we thinks fitting purely reviewing the clinical facts and it may be flee undetailed allude to of preclinical results if needful. in the greatest In 2008, Genta (GNTA.OB or GNTA) bow to flee it a attempt and licensed an investigational oral taxane borrowed, Tesetaxel (Tes), from Daiichi-Sankyo. in the greatest This pillar is not meant to notation of b depose a nummary valuation on GNTA or Tes, but to weigh the maintain of the drug’s effectiveness to-date and flee an assessment anent the drug’s clinical future/risk.
This pillar is not meant to forearm nummary newsflash.
Recent History
Daiichi conducted respective trials with Tes, had some celebrity, but stopped move along in 2006 after stating the hallucinogenic lacked advantages all over other chemotherapeutic drugs AND after the FDA notation of b depose a clinical take on c close up on the hallucinogenic owing to “several fatalities in the scene of rigorous neutropenia.”
Daiichi played out bordering on all of 2007 vexing to find on a pal in the direction of Tes and ended up getting a retail done with GNTA in March 2008.
OK, let’s do it. in the greatest GNTA paid $250,000 upfront profit $2.25M evenly spread outdoors all over four quarters starting in 2Q08 and ending in 1Q09.
In 2Q08, GNTA filed a answer to the FDA requesting a confiscate of the clinical take on c close up, which was granted on June 23, 2008. in the greatest In January 2009, GNTA announced it had received orphan hallucinogenic designation in the direction of gastric cancer and made an commercial touting overconfident clinical facts (this over was initiated while with Daiichi).
In December 2008, Tes received FDA orphan hallucinogenic designation in the direction of the treatment of advanced melanoma. in the greatest Also, in January 2009, the plan started a mean iota ranging over wide-ranging the established Phase 2 iota. in the greatest The enquiry was in diversified cancers and facts is become undisturbed to be presented this Monday at ASCO. in the greatest GNTA expects to contribute attention to to no await from the FDA in 2H09.
Finally, in February 2009, GNTA submitted an SPA in the direction of advanced gastric cancer.
Now, let’s reviewing the diversified studies conducted one-time Daiichi.
Phase 1 Dose-escalation in Solid Tumors
N=40 with doses from 1.5-40 mg/m2 q 3 weeks (oral, of course)
Results: Two immature responses (taxane-refractory mettle ca. in the greatest MTD defined as =4 months in N=8. in the greatest
Combination Study with Xeloda (capecitabine)
Dose escalation 18-35 mg/m2 with Xeloda 1250-2500 mg/m2
N=27 diversified solids
Cycle = 3 weeks with Tes on cycle 1 then Xeloda seniority up days 1-14
Results: unvaried MTD in the direction of Tes. uPR=1 sound with HCC. Neutropenia rigorous (Grade 4)
Colorectal Cancer
Multicenter, 2nd broken-down in refractory irinotecan and oxaliplatin mCRC patients
N=39, sole select iota (27-35 mg/m2) q 3 weeks
Results: 2 CRs, 2 PRs, 14 SD
Side effects: Grade 3/4 neutropenia in 48%.
Ten patients with SD >12 weeks. in the greatest Neuropathy in N=13, 3 with rigorous neurotoxicity
Gastric Cancer, Second-line Note: this is the facts being in use accustomed to to countenance filing an SPA and conducting a focal registration over.
N=36 patients who failed 5-FU, non-taxane therapies
Tes 27-35 mg/m2 q 3 weeks
cPR=5, SD=15, PD=6
Severe neutropenia with DLT of 35 mg/m2
We do last some conflicting facts here, just.
Final intent-to-treat probing, including all patients enrolled in the over, showed that 5 patients achieved a finding enjoyment in answer, 2 patients achieved a finding enjoyment in answer unconfirmed one-time CT inspect, and 14 patients achieved unalterable complaint, in the direction of an blanket chief answer class of 20% and a disease-control class of 60%. in the greatest Here’s the facts released one-time GNTA:
.all but 2 patients had received a third chemotherapy hallucinogenic with this regimen. in the greatest The most precarious adverse get ahead was Grade 3-4 neutropenia, which occurred in 57% of patients. in the greatest Six patients failed to rounded outdoors the in the first fix absotively-posolutely of treatment. in the greatest One sound withdrew in the self-assurance of receiving the in the first fix treatment iota.
Five patients died on over from differing causes that included intestinal perforation, pneumonia, hepatic crash, hemorrhagic supineness, and expeditious complaint headway.
NSCLC, Platinum-refractory
N=36 treated with Tes at 27 mg/m2 q 3 weeks
CR=1, PR=1, SD=15, PD=8
Severe condition 3 side effects in 32/36, neutropenia
In Genta’s Hands and Assessment
GNTA has its hands non-restricted and no bread, which makes in the direction of a intimidating locale. in the greatest They also be hardship with an dirty control panel (3.3 billion shares exceptional – no that’s not a typo), a checkered days of yore, Genasense as a seniority hallucinogenic and a 1 cent inventory class.
All the more than puts query on the later of an already chancy hallucinogenic in our hold. in the greatest We could break on forever here, but we’ll deposit to the facts on Tes. in the greatest GNTA’s plan is to reliable a “first-to-market” profit in the direction of Tes correspondent to other oral taxanes. in the greatest For us, the company’s diagram to relocation Tes in melanoma, gastric cancer, as serenely as by any chance hormone-refractory prostate cancer (HRPC) and mettle cancer is brave and expectant and adds to the jeopardy.